

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Debnath, et al.)
 Serial Number: 10/577,698) Examiner: Brian E. McDowell
 Filed: April 28, 2006) Group Art Unit: 1624
 Confirmation No.: 3725) Customer Number: 22827
 Title: Novel Compounds and Their Use)
 in Medicine, as Antidiabetic and)
 Hypolipidemic Agents, Process)
 for Their Preparation and)
 Pharmaceutical Compositions)
 Containing Them)

AMENDMENT

Commissioner for Patents
 Post Office Box 1450
 Alexandria, VA 22313-1450

Dear Sir:

This is a response/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is to be treated as the signature to the attachment in absence of a signature thereto.

Fee requirements (if any) have been calculated as shown below:

	Claims remaining after amendment	Highest number previously paid for	Present Extra	Additional Fee
Total Effective Claims	9	minus	= 0	X \$ 52 = \$ 0.00
Independent Claims	1	minus	= 0	X \$220 = \$ 0.00

A Request for Continued Examination is requested in view of the: (\$810) \$ 0.00

Previously submitted Amendment / Response dated _____

Enclosed Amendment / Reply

Enclosed Affidavit(s) / Declaration(s)

Enclosed Information Disclosure Statement

Since Official Action set an original due date of _____,
PETITION is hereby made for an extension to cover the date this
 response is filed for which the requisite fee is enclosed (1 month \$130;
 2 months \$490; 3 months \$1,110; 4 months \$1,730, 5 months \$2,350 \$ 0.00

If amendment enters proper multiple dependent claim(s) into this application
 for first time, add \$390.00 (per application) \$ 0.00

If Terminal Disclaimer enclosed, add Rule 20(d) Official Fee (\$140.00) \$ 0.00

Other: _____ \$ 0.00

SUBTOTAL: \$ 0.00

If "small entity" verified statement filed previously,
 herewith, enter one-half (½) of subtotal and subtract \$ 0.00

TOTAL FEE ENCLOSED: \$ 0.00

The Commissioner is hereby authorized to charge any fee specifically authorized
 hereafter, or any fees in addition to the fee(s) filed, or asserted to be filed, or which
 should have been filed herewith or concerning any paper filed hereafter, and which may
 be required under Rules 16-18 (deficiency only) now or hereafter relative to this
 application and the resulting official document under Rule 20, or credit any
 overpayment, to our Account No. shown in the heading hereof. This statement does not
authorize charge of the issue fee in this case.

DORITY & MANNING ATTORNEYS AT LAW, P.A.

ADDRESS:

Post Office Box 1449
 Greenville, SC 29602 USA
 Customer ID No.: 22827
 Telephone: (864) 271-1592
 Facsimile: (864) 233-7342

By: Douglas L. Lineberry Reg. No: 54,274

Signature: 

Date: April 29, 2009

I hereby certify that this correspondence and all attachments and any fee(s) are being
 electronically transmitted via the internet to the U.S. Patent and Trademark Office using
 the Electronic Patent Filing System on April 29, 2009.

Tara W. Somers

(Typed or printed name of person transmitting documents)

Tara W. Somers

(Signature of person transmitting documents)

PATENT
ATTORNEY DOCKET NO: RED-18-PCT-US (DRF33029)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application: Debnath, et al.)	Examiner: Brian E. McDowell
Serial No: 10/577,698)	Group Art Unit: 1624
Filed: April 28, 2006)	Confirmation No: 3725
Title: Novel Compounds and Their Use		Account No: 04-1403
In Medicine, as Antidiabetic and)
Hypolipidemic Agents, Process)
For Their Preparation and)
Pharmaceutical Compositions)
Containing Them)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT AND RESPONSE TO 03/04/09 OFFICE ACTION

Dear Sir:

In response to the Office Action dated March 4, 2009, please refer to the following remarks:

Amendments to the Abstract begin on page 2 of this paper.

Amendments to the Claims begin on page 3 of this paper.

Remarks begin on page 10 of this paper.